Madrigal Pharmaceuticals (MDGL) Accumulated Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Accumulated Expenses for 17 consecutive years, with $338.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Accumulated Expenses rose 115.05% year-over-year to $338.7 million; the TTM figure through Jun 2026 stood at $338.7 million (up 115.05% YoY), while the FY2025 annual figure was $260.4 million, up 108.82% from the prior year.
• Accumulated Expenses rose to $338.7 million in Q2 2026 per MDGL's latest filing, from $275.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $345.4 million in Q3 2025 and bottomed at $53.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $144.5 million across 5 years, with a median of $103.9 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses slipped 1.62% — and 2025, when it soared 163.64%.
• Madrigal Pharmaceuticals' Accumulated Expenses stood at $91.5 million in 2022, then slipped by 1.62% to $90.0 million in 2023, then jumped by 38.58% to $124.7 million in 2024, then soared by 108.82% to $260.4 million in 2025, then surged by 30.06% to $338.7 million in 2026.
• Business Quant data shows MDGL's Accumulated Expenses at $338.7 million in Q2 2026, $275.8 million in Q1 2026, and $260.4 million in Q4 2025.